...
首页> 外文期刊>Archives of pharmacal research >Effects of protein transduction domain (PTD) selection and position for improved intracellular delivery of PTD-Hsp27 fusion protein formulations
【24h】

Effects of protein transduction domain (PTD) selection and position for improved intracellular delivery of PTD-Hsp27 fusion protein formulations

机译:蛋白质转导域(PTD)选择和位置对改善PTD-Hsp27融合蛋白制剂胞内递送的影响

获取原文
获取原文并翻译 | 示例

摘要

Protein drugs have attracted considerable attention as therapeutic agents due to their diversity and biocompatibility. However, hydrophilic proteins possess difficulty in penetrating lipophilic cell membrane. Although protein transduction domains (PTDs) have shown effectiveness in protein delivery, the importance of selection and position of PTDs in recombinant protein vector constructs has not been investigated. This study intends to investigate the significance of PTD selection and position for therapeutic protein delivery. Heat shock protein 27 (Hsp27) would be a therapeutic protein for the treatment of ischemic heart diseases, but itself is insufficient to prevent systemic degradation and overcoming biochemical barriers during cellular transport. Among all PTD-Hsp27 fusion proteins we cloned, Tat-Hsp27 fusion protein showed the highest efficacy. Nona-arginine (9R) conjugation to the N-terminal of Hsp27 (Hsp27-T) showed higher efficacy than C-terminal. To test the synergistic effect of two PTDs, Tat was inserted to the N-terminal of Hsp27-9R. Tat-Hsp27-9R exhibited enhanced transduction efficiency and significant improvement against oxidative stress and apoptosis. PTD-Hsp27 fusion proteins have strong potential to be developed as therapeutic proteins for the treatment of ischemic heart diseases and selection and position of PTDs for improved efficacy of PTD-fusion proteins need to be optimized considering protein's nature, transduction efficiency and stability.
机译:蛋白药物由于其多样性和生物相容性而作为治疗剂引起了相当大的关注。但是,亲水性蛋白质难以渗透亲脂性细胞膜。尽管蛋白质转导域(PTD)已显示出有效的蛋白质传递,但尚未研究PTD在重组蛋白质载体构建体中的选择和位置的重要性。这项研究旨在调查PTD选择和治疗性蛋白传递的位置的意义。热休克蛋白27(Hsp27)将是一种治疗性缺血性心脏病的治疗蛋白,但其本身不足以防止系统性降解和克服细胞运输过程中的生化障碍。在我们克隆的所有PTD-Hsp27融合蛋白中,Tat-Hsp27融合蛋白显示出最高的功效。九氨酸精氨酸(9R)与Hsp27(Hsp27-T)N末端的缀合显示出比C末端更高的功效。为了测试两个PTD的协同作用,将Tat插入Hsp27-9R的N端。 Tat-Hsp27-9R表现出增强的转导效率和对氧化应激和细胞凋亡的显着改善。 PTD-Hsp27融合蛋白具有开发作为治疗缺血性心脏病的治疗蛋白的强大潜力,需要考虑蛋白质的性质,转导效率和稳定性来优化PTD的选择和位置,以提高PTD融合蛋白的功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号